about
Long-Term Changes of Subcutaneous Fat Mass in HIV-Infected Children on Antiretroviral Therapy: A Retrospective Analysis of Longitudinal Data from Two Pediatric HIV-Cohorts.Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late?Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.CAVITATION OF THE GHON FOCUS IN AN HIV-INFECTED INFANT WHO ACQUIRED TUBERCULOSIS AFTER THE INITIATION OF HAART.Comparative study of different brands of stavudine capsules for the off-label 'opened capsule' dosing method recommended for HIV-infected infants and children in resource-limited settings.LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.White matter signal abnormalities in children with suspected HIV-related neurologic disease on early combination antiretroviral therapyManagement of upper respiratory tract infections in childrenEarly antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis.High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral TherapyEffect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.Bioequivalence of dispersed stavudine: opened versus closed capsule dosingEstimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children.Late Onset HIV Encephalopathy in Children with Long-Standing Virologic Suppression Followed by Slow Spontaneous Recovery despite No Change in Antiretroviral Therapy -Four Case Reports.Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study.Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland.Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing
P50
Q30978868-4031C854-33B3-488C-87F1-C9811F785A6EQ33750539-9EBD9874-9D19-47A2-AF65-2BDB97AB2555Q33926151-C6BAE085-DE30-4602-B1D1-BE85DF265396Q33941548-005BABE8-53FA-49D7-801E-CD23B742EF92Q33999846-DC6EAB24-DAC6-4A34-88CA-A9E8DB240F2DQ34058478-66700856-40FF-4EFF-B45A-A07BE8619250Q34129550-D3D02B62-E8B3-44E6-B8B5-C47CCC97B983Q34994841-82A3F396-1413-485F-9C29-13EF58F076ACQ35246507-E5428BE9-E887-4A39-BEB6-6BFA6387CC7BQ36449095-9FB66A6D-19E8-475E-806A-97166CC351A5Q36558893-01266672-4E05-4099-AFE6-98DABF0D0042Q36646867-871F641A-A51B-4556-81B7-132199771141Q37318648-925FB350-5DD5-4921-9325-DEE631407898Q37544710-A6A72080-BEAE-4155-85BB-9069C2E8E711Q37724319-FD723931-6251-4A0E-B43F-D869F4EBC22DQ40118266-659E424D-BDB2-4C87-9456-38AEB92AE1F9Q42228986-68ADD62E-0584-4605-8A3B-9A07CB657144Q50063465-9BB5E7C5-E382-4B5B-876E-172FE1DB93D5Q53695978-B6C4A916-FD05-4CE2-A073-8157D487B258Q57789801-6A1F2B0D-D8A2-4D31-9514-98E74FDA4BF3
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Steve Innes
@ast
Steve Innes
@en
Steve Innes
@es
Steve Innes
@nl
Steve Innes
@sl
type
label
Steve Innes
@ast
Steve Innes
@en
Steve Innes
@es
Steve Innes
@nl
Steve Innes
@sl
prefLabel
Steve Innes
@ast
Steve Innes
@en
Steve Innes
@es
Steve Innes
@nl
Steve Innes
@sl
P106
P1153
24335146400
P21
P31
P496
0000-0003-3969-8680